Fiche publication
Date publication
juillet 2024
Journal
The New England journal of medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M,
Lien Pubmed
Résumé
The efficacy and safety of risankizumab as compared with ustekinumab in patients with Crohn's disease are unknown.
Mots clés
Humans, Crohn Disease, drug therapy, Ustekinumab, therapeutic use, Male, Female, Adult, Middle Aged, Antibodies, Monoclonal, therapeutic use, Remission Induction, Severity of Illness Index, Intention to Treat Analysis, Young Adult
Référence
N Engl J Med. 2024 07 18;391(3):213-223
